Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Hemispherx BioPharma, Inc (AMEX:HEB)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | SEC | Msgs | Insider | Options | Financials | Reports
Recent Events
Aug 16Earnings Announcement
Location
1617 JFK Boulevard, Suite 660
Philadelphia, PA 19103
Phone: (215) 988-0080
Fax: (215) 988-1739
Email: webmaster@hemispherx.com
Employees (last reported count): 23
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Products & Services
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 17%
·Institutional: 7% (9% of float)
(38 institutions)
·Net Inst. Buying: 1.06M shares (+32.07%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Hemispherx BioPharma, Inc. is a pharmaceutical research and development company using nucleic acid technologies to develop therapeutic products for the treatment of certain viral diseases and cancers. The Company's proprietary drug technology utilizes specifically configured ribonucleic acid (RNA). Hemishperx has established a base of laboratory, pre-clinical and clinical data to support the commercialization of its lead compound, Ampligen, for use in treating immune system dysfunction, viral diseases and certain cancers. Ampligen is undergoing Phase II/III clinical trials in the United States and Europe for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue syndrome. The Company's three domestic subsidiaries include BioPro Corp., BioAegean Corp. and Core BioTech Corp. Its foreign subsidiary, Hemispherx BioPharma Europe, N.V./S.A., was established in 1998.
More from Market Guide: Expanded Business Description

Financial Summary
HEB and its subsidiaries is a biopharmaceutical co. using nucleic acid technologies to develop therapeutic products for the treatment of viral diseases and certain cancers. For the six months ended 6/30/01, revenues decreased 46% to $228 thousand. Net loss increased 20% to $4.8 million. Revenues reflect decreased cost recovery from clinical treatment programs. Higher loss suffered from increased research and development expenditures.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]

Position
William Carter, M.D., 62Chairman, Pres, CEO
Robert Peterson, 63CFO
Harris Freedman, 65VP for Strategic Alliances
Josephine Dolhancryk, 37Treasurer and Assistant Secretaty
Carol Smith, Ph.D., 48Director of Manufacturing and Process Devel.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- AMEX:HEBAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Mar-2001
$3.01 
Recent Price$4.80 
52-Week High
on 12-Sep-2000
$8.188
Beta-0.38 
Daily Volume (3-month avg)55.2K
Daily Volume (10-day avg)38.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-24.7%
52-Week Change
relative to S&P500
+1.0%
Share-Related Items
Market Capitalization$145.6M
Shares Outstanding30.3M
Float25.2M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$0.27 
Earnings (ttm)-$0.31 
Earnings (mrq)-$0.08 
Sales (ttm)$0.02 
Cash (mrq)$0.16 
Valuation Ratios
Price/Book (mrq)17.74 
Price/EarningsN/A 
Price/Sales (ttm)242.99 
Income Statements
Sales (ttm)$590.0K
EBITDA (ttm)-$9.12M
Income available to common (ttm)-$9.34M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-75.59%
Return on Equity (ttm)-83.72%
Financial Strength
Current Ratio (mrq)4.93 
Debt/Equity (mrq)0 
Total Cash (mrq)$4.98M
Short Interest
As of 8-Aug-2001
Shares Short1.83M
Percent of Float7.3%
Shares Short
(Prior Month)
0 
Short Ratio73.16 
Daily Volume25.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.